Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 60429-164

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60429-164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60429 164 60lb

Label for Duloxetine Delayed-Release Capsules, USP 20 mg by Golden State Medical Supply, Inc. The label includes the NDC 60429-164-60 and states each capsule contains 22.4 mg of duloxetine hydrochloride USP equivalent to 20 mg duloxetine. It displays a package size of 60 capsules, with storage instructions and manufacturer details (Towa Pharmaceuticals Europe, S.L.). The label also advises pharmacists to dispense a medication guide to patients.*

FDA Label Image

60429 165 30lb

Label for Duloxetine Delayed-Release Capsules USP 30 mg, manufactured by Towa Pharmaceuticals Europe, S.L., and marketed by GSMS, Incorporated. The label includes dosage strength, package size of 30 capsules, a barcode, storage instructions, and dispensing information. The NDC number is 60429-165-30.*

FDA Label Image

60429 166 30lb

Label for Duloxetine Delayed-Release Capsules USP, 60 mg strength, by Golden State Medical Supply, Inc. The label shows a 30-capsule count with NDC 60429-166-30. It includes dosage and storage details, a barcode, and manufacturer information (Towa Pharmaceuticals Europe, S.L.). The label is marked Rx Only.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of Duloxetine hydrochloride, the active ingredient in Duloxetine Delayed-Release 20 mg capsules by Golden State Medical Supply, Inc.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the proportion of patients with relapse over time in days from randomization, comparing Duloxetine delayed-release capsules to placebo. The graph features two curves, with the Duloxetine group showing a lower relapse proportion over approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line chart showing the proportion of patients with relapse over time (days) from randomization. Two treatment groups are compared: placebo (dashed line) and duloxetine delayed-release capsules (solid line). The chart illustrates that patients on duloxetine had a lower proportion of relapse over the observed period compared to placebo.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Four groups shown: Duloxetine (DUL) 60 mg twice daily, DUL 60 mg once daily, DUL 20 mg once daily, and placebo. The graph compares pain improvement across these treatment groups.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for three groups: DUL 60mg BID, DUL 60mg QD, and placebo. The x-axis shows percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. The graph illustrates trends over a range of improvement percentages for each group.*

FDA Label Image

Figure 7 (Duloxetine 06)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: DUL 60mg Twice Daily, DUL 60mg Once Daily, and Placebo, illustrating patient improvement trends across different pain improvement levels.*

FDA Label Image

Figure 8 (Duloxetine 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. Each line shows a decline in patient improvement as pain improvement percentage increases, with placebo generally showing the lowest improvement.*

FDA Label Image

Figure 9 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It features two data series: placebo and Duloxetine (DUL) 60/120 mg once daily, showing patient improvement trends across varying degrees of pain reduction.*

FDA Label Image

Principal Display Panel (20 mg Capsule Bottle Label)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Two lines compare placebo and Duloxetine (DUL) 60 mg once daily treatment groups, illustrating differences in patient outcomes across varying levels of pain improvement.*

FDA Label Image

Principal Display Panel (30 mg Capsule Bottle Label)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: placebo and Duloxetine Delayed-Release 60/120 mg once daily, illustrating a higher percentage of pain improvement in the Duloxetine group across various improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.